Vertex Pharmaceuticals Inc (VRTX)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	4,379,800	4,309,000	4,306,200	4,169,100	4,232,400	4,026,500	3,932,900	2,864,300	2,730,400	2,748,123	2,411,194	3,280,164	3,116,798	2,905,125	2,229,920	1,732,288	1,394,919	775,897	842,032	732,595
Revenue (ttm)	US$ in thousands	9,803,200	9,596,700	9,444,700	9,144,300	8,863,500	8,628,770	8,277,080	7,873,370	7,499,400	7,066,960	6,622,470	6,355,190	6,147,530	5,935,020	5,347,582	4,763,428	4,106,025	3,577,111	3,416,521	3,232,116
Pretax margin		44.68%	44.90%	45.59%	45.59%	47.75%	46.66%	47.52%	36.38%	36.41%	38.89%	36.41%	51.61%	50.70%	48.95%	41.70%	36.37%	33.97%	21.69%	24.65%	22.67%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $4,379,800K ÷ $9,803,200K
= 44.68%

The pretax margin of Vertex Pharmaceuticals, Inc. has shown fluctuations over the past eight quarters, ranging from 36.04% in Q1 2022 to a peak of 47.39% in Q4 2022. In the most recent quarter, Q4 2023, the pretax margin stands at 44.38%, slightly lower than the previous quarter at 44.63% in Q3 2023. Overall, Vertex Pharmaceuticals has maintained relatively high pretax margins above 40% in most quarters, indicating efficient cost management and profitability in their operations.